Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000641354 | SCV000762995 | likely benign | Nemaline myopathy 2 | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000641354 | SCV001525407 | uncertain significance | Nemaline myopathy 2 | 2019-10-01 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Gene |
RCV001766379 | SCV001989031 | uncertain significance | not provided | 2021-06-16 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 27535533) |
Revvity Omics, |
RCV001766379 | SCV003810192 | uncertain significance | not provided | 2022-10-28 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004547805 | SCV004776733 | likely benign | NEB-related disorder | 2021-06-02 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Natera, |
RCV000641354 | SCV001456462 | uncertain significance | Nemaline myopathy 2 | 2019-11-11 | no assertion criteria provided | clinical testing |